Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12683588 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3272711 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL1320424 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL3277927 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL1843641 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL22869197 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL7572788 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL736958 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL8696423 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19LCK | |
| SCHEMBL21552247 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | Georgetown University Office of Technology Commercialization (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | Georgetown University Office of Technology Commercialization (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | Georgetown University Office of Technology Commercialization (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2007115092-A2 | 10-SUBSTITUTED CYTISINE DERIVATIVES AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-7132551-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2005077463-A2 | LIGAND FOR A MONOAMINE RECEPTOR OR TRANSPORTER FOR TREATING ADDICTION OR DEPENDENCE | SEPRACOR INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | SEPRACOR, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | AQUILA BRIAN M (US) | 2004-04-22 | — | — | US | disclosed |
| EP-1318988-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | Sepracor, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | PNMT, TAAR1, OPRL1 | SMN1; SMN2 3005/4885NPC1 1102/4885RAB9A 3636/4885 |
| US-20100048606-A1 | 10-Substituted Cytisine Derivatives and Methods of Use Thereof | CHRNA10, CHRNA5, CHRNA1 | SMN1; SMN2 2088/4885NPC1 1762/4885RAB9A 1275/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | SMN1; SMN2 872/4885NPC1 145/4885RAB9A 1348/4885 |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | SMN1; SMN2 872/4885NPC1 145/4885RAB9A 1348/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | SMN1; SMN2 872/4885NPC1 145/4885RAB9A 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.